Search PubMed⌕ Search

Biomedical subjects

J W Blake

Publications and source records attributed to J W Blake.

At least 37 records · Page 2Linked to original sources
PubMed1986

High-sensitivity radioimmunoassay screening method for fentanyl.

A radioiodinated analog of fentanyl was synthesized for use with a commercially available radioimmunoassay for fentanyl. The sensitivity of the modified assay was at least 100 times greater than that of the original assay. Using this modified assay, concentrations of fentanyl as low as 1 pg/ml of fentanyl or fentanyl equivalents in equine urine were detected. Doses of fentanyl 100 times smaller than the minimum dose for a pharmacologic effect were detectable and a pharmacologically effective dose of fentanyl was detectable for up to 96 hours or more. The high sensitivity of the assay indicated that large numbers of urine samples (ie, 10 to 20) probably could be pooled and screened simultaneously, which would result in an economical analysis for fentanyl in the urine of horses after a race. Sufentanil and its metabolites also were detectable, using this assay, but at only about 1% of the efficiency at which fentanyl was detectable.

Animals↗
PubMed1986

Radioimmunoassay screening for etorphine in racing horses.

A commercially available radioimmunoassay kit was used to screen for the presence of etorphine in post-race urines from horses racing in Kentucky. Most horse urines contained small amounts of materials which reacted positively in this immunoassay. These materials are apparently endogenous to the horse and were called apparent etorphine equivalents. The levels of these apparent etorphine equivalents in post-race urines from 70 horses were estimated. Their modal level averaged 0.1 ng/ml, the population distribution was log normal, and individual horses showed levels of up to 0.8 ng/ml.

Animals↗
PubMed1985

Efficacy of testing for illegal medication in horses.

The efficacy of testing for illegal drugs in race horses was surveyed by evaluating 27 questionnaires received from 28 racing jurisdictions polled. Large variations in the number of samples tested and drugs detected were reported. Some jurisdictions reported only illegal medications, whereas others also reported permitted medications. To facilitate comparison, stimulants, depressants, local anesthetics, narcotic analgesics, and tranquilizers were classified as hard drugs. Other drugs, which are legal in some jurisdictions, were classified as soft. To evaluate the efficacy of testing, positive test results were compared for hard drugs only. Positive test results varied from zero in some jurisdictions for some years to 14.8/1,000 samples tested for one small jurisdiction in one year. The mean rates over the years 1975 to 1983 varied from 0.2 to 6.5/1,000, with a modal positive test result of about 1/1,000. Beside the fact that prerace blood testing is less effective than is postrace urine testing, no cause for these variations in the positive test results could be identified. The positive test results also were compared for jurisdictions with differing medication rules for phenylbutazone (PBZ). Jurisdictions that did not allow PBZ had a mean positive test result for hard drugs of about 1.3 +/- 0.9/1,000 samples tested. Jurisdictions that allowed more liberal use of PBZ had a mean positive test result for hard drugs of about 1.3 +/- 1.0/1,000 samples tested. Seemingly, the presence of PBZ in equine forensic samples did not reduce the ability of forensic laboratories to detect the use of hard or illegal drugs.

Animals↗
PubMed1985

The metabolic fate of 2,4-dichlorophenoxyacetic acid-n-butyl ester in the Wistar rat.

The metabolic fate of 2,4-dichlorophenoxyacetic acid (2,4-D)-n-butyl ester in rats has not been extensively studied. Upon subcutaneous administration of a 100 mg/kg dose of 2,4-D butyl ester to four male Wistar rats, urine samples were analyzed by three analytical techniques for the presence of the butyl ester and metabolites. Thin layer chromatography (TLC), gas chromatography using an electron capture detector (GC-ECD), and gas chromatography-mass spectroscopy (GC-MS) were the techniques employed. 2,4-D butyl ester was rapidly hydrolyzed in the body to form 2,4-D acid. Ninety-five percent of the administered dose was excreted into the urine as the free acid within 48 h of injection, while only a small fraction (5%) was excreted over an additional 48 h. No amino acid conjugates or the parent 2,4-D butyl ester could be detected in the urine of treated rats. A minor metabolite (less than or equal to 2% of dose) was detected by GC-MS analysis of urine samples. This compound appears to be a side chain metabolite of the 2,4-D butyl ester. Some chemical properties of the metabolite were characterized, and a 2,4-D hydroxyethyl ester structure proposed. The mechanism of this minor metabolic formation remains unknown.

2,4-Dichlorophenoxyacetic Acid↗
PubMed1985

Phenylbutazone and its metabolites in plasma and urine of thoroughbred horses: population distributions and effects of urinary pH.

A survey of plasma and urinary concentrations of phenylbutazone and its metabolites in thoroughbred horses racing in Kentucky was carried out. Post-race blood samples from more than 200 horses running at Latonia Racetrack and Keeneland in the Spring of 1983 were analysed. The modal plasma concentration of phenylbutazone was between 1 and 2 micrograms/ml, the mean concentration was 3.5 micrograms/ml and the range was up to 15 micrograms/ml. Oxyphenbutazone had a modal plasma concentration between 1 and 2 micrograms/ml, a mean concentration of 2.07 micrograms/ml and a range of up to 13 micrograms/ml. gamma OH-phenylbutazone had a modal plasma concentration of less than 1 microgram/ml, a mean level of 1.39 micrograms/ml and a range of up to 7.32 micrograms/ml. All plasma concentration frequency distributions were well fitted by log normal distributions. Urinary concentrations of phenylbutazone yielded modal concentrations of less than 1 microgram/ml, a mean urinary concentration of 2.9 micrograms/ml, with a range of up to 30.5 micrograms/ml. This population fitted a log-normal distribution. For oxyphenbutazone the modal concentration was less than 3 micrograms/ml, the mean concentration was 15.26 micrograms/ml, with a range to 81.5 micrograms/ml. The frequency distribution of these samples was apparently bimodal. For gamma OH-phenylbutazone, the modal concentration was less than 4 micrograms/ml, the mean concentration 21.23 micrograms/ml, with a range of up to 122 micrograms/ml. The population frequency distribution for gamma OH-phenylbutazone was indeterminate. Analysis of the pH of these post-race urine samples showed a bimodal frequency distribution. The pH values observed ranged from 4.9 to 8.7, with peaks at about pH 5.25 and 7.25. This bimodal pattern of urinary pH values is consistent with observations made in England and Japan. Urinary pH influenced the concentrations of phenylbutazone, oxyphenbutazone and gamma OH-phenylbutazone found in the urine samples. The concentration of these metabolites found in alkaline urines were from 32 to 225 times greater than those found in acidic urines. Plasma concentrations of phenylbutazone and its metabolites, however, were unaffected by urinary pH. In interlaboratory experiments, horses running at Hollywood Park were dosed with phenylbutazone at about 2 g/1000 lbs 24 and 48 h before racing, and a mean dose of 0.6 g/1000 lbs at 72 h prior to racing. Post-race plasma samples from these horses showed phenylbutazone concentrations ranging from 0.44 to 9.97 micrograms/ml, with a mean concentration of 4.09 micrograms/ml.(ABSTRACT TRUNCATED AT 400 WORDS)

Animals↗
PubMed1985

Effects of phenylbutazone and oxyphenbutazone on basic drug detection in high performance thin layer chromatographic systems.

Interference or 'masking' in thin layer chromatography occurs when the presence of one drug on a thin layer plate physically obscures or interferes with the detection of another drug. We investigated the ability of phenylbutazone and oxyphenbutazone to mask or interfere with the detection by high performance thin layer chromatography (HPTLC) of basic drugs used illegally in horse racing. Of fifty-five basic drugs called 'positive' since 1981 by laboratories affiliated with the Association of Official Racing Chemists (AORC), forty did not comigrate with phenylbutazone or oxyphenbutazone and could not, therefore, be masked. When 75 micrograms/ml of oxyphenbutazone was spiked into urine samples, subjected to an extraction procedure for basic drugs, and then run in our routine HPTLC systems, no 'spots' due to oxyphenbutazone appeared. 'Masking' by oxyphenbutazone, therefore, did not and could not occur in our test systems. When phenylbutazone at a concentration of 30 micrograms/ml was spiked into urine samples and run in the routine HPTLC system, phenylbutazone spots were visible under ultraviolet light and after certain specific oversprays were used to visualize basic drugs. These spots, however, did not interfere with routine thin layer testing for basic drugs. It was concluded that phenylbutazone and oxyphenbutazone had no significant ability to interfere with detection of the parent forms of these basic drugs under the conditions described in these experiments.

Animals↗
PubMed1984

Biosynthesis of the potent carcinogen 7,12-dimethylbenz[a]anthracene.

Earlier studies from this laboratory of the metabolism of 7,12-dimethylbenz[a]anthracene (DMBA) and of benzo[a]pyrene as well as studies of mutagenic and carcinogenic activity of some of the metabolic products led to the concept that a necessary first step in carcinogenesis by most alkyl substituted polycyclic hydrocarbons is biotransformation to a meso-anthracenic hydroxyalkyl metabolite, whereas most hydrocarbons lacking alkyl substituents undergo a bio-alkylation substitution reaction in the mesoanthracenic position(s) or L-region as a necessary first step in carcinogenesis. According to this unified hypothesis, all strong polycyclic hydrocarbon carcinogens must either, themselves, bear a meso-anthracenic alkyl substituent or else undergo a bio-alkylation substitution reaction in vitro and in vivo. Here we report that the weak carcinogen benz[a]anthracene undergoes meso-anthracenic methylation by S-adenosyl-L-methionine (SAM), in the presence of a rat liver cytosol preparation, in vitro, to form DMBA and presumably the moderately active carcinogens 7-methylbenz[a]anthracene and 12-methylbenz[a]anthracene. These compounds are substrates for further L-region methylation to form the strong carcinogen, DMBA.

9,10-Dimethyl-1,2-benzanthracene↗
PubMed1984

Population distributions of phenylbutazone and oxyphenbutazone after oral and i.v. dosing in horses.

Experiments to determine the residual plasma concentrations of phenylbutazone and its metabolites found in horses racing on a 'no-race day medication' or 24-h rule were carried out. One dosing schedule (oral-i.v.) consisted of 8.8 mg/kg (4 g/1000 lbs) orally for 3 days, followed by 4.4 mg/kg (2 g/1000 lbs) intravenously on day 4. A second schedule consisted of 4.4 mg/kg i.v. for 4 days. The experiments were carried out in Thoroughbred and Standardbred horses at pasture, half-bred horses at pasture, and in Thoroughbred horses in training. After administering the i.v. schedule for 4 days to Thoroughbred and Standardbred horses at pasture, the mean plasma concentrations of phenylbutazone increased from 0.77 microgram/ml on day 2 to 2.5 micrograms/ml on day 5. The shape of the frequency distribution of these populations was log-normal. These data are consistent with one horse in 1,000 yielding a plasma level of 8.07 micrograms/ml on day 5. After administration of the oral-i.v. schedule to Thoroughbred and Standardbred horses at pasture, the mean plasma concentrations of phenylbutazone were 3.4 micrograms/ml on day 2 and 3.5 micrograms/ml on day 5. The range on day 5 was from 1.4 to 8.98 micrograms/ml and the frequency distribution was log-normal. These data are consistent with one horse in 1000 having a plasma level of 15.8 micrograms/ml on day 5. In a final experiment, the oral dosing schedule was administered to 62 Thoroughbred horses in training. Plasma concentrations on day 5 in these horses averaged 5.3 micrograms/ml. The range was from 1.3 to 13.6 micrograms/ml and the frequency distribution was log-normal. Statistical projection of these values suggests that following this oral dosing schedule in racing horses about one horse in 1000 will yield a plasma level of 23.5 micrograms/ml of phenylbutazone 24 h after the last dose.

Administration, Oral↗
PubMed1982

The pharmacokinetics, pharmacological responses and behavioral effects of acepromazine in the horse.

After intravenous (i.v.) injection, acepromazine was distributed widely in the horse (Vd = 6.6 litres/kg) and bound extensively (greater than 99%) plasma proteins. Plasma levels of drug declined with an alpha half-life of 4.2 min, while the beta phase or elimination half-life was 184.8 min. At a dosage level of 0.3 mg/kg acepromazine was detectable in the plasma for 8 h post dosing. The whole blood partitioning of acepromazine was 46% in the plasma phase and 54% in the erythrocyte phase. Penile prolapse was clearly evident at doses from 0.01 mg/kg to 0.4 mg/kg i.v., and the duration and extent of protrusion were dose related. Hematocrit levels were significantly lowered by administration of 0.002 mg/kg i.v. (about 1 mg to a 500 kg horse) and increasing dosages resulted in greater than 20% lowering of the hematocrit from control levels. Pretreatment of horses with acepromazine also reduced the variable interval (VI 60) responding rate in all horses tested. These data show that hematocrit changes are the most sensitive pharmacological responses to acepromazine, followed by changes in penile extension, respiratory rate, VI responding and locomotor responses. Acepromazine is difficult to detect in plasma at normal clinical doses. However, because of its large volume of distribution, its urinary elimination is likely prolonged, and further work on its elimination in equine urine is required.

Acepromazine↗
PubMed1982

Furosemide, Patella vulgata beta-glucuronidase and drug analysis: conditions for enhancement of the TLC detection of apomorphine, butorphanol, hydromorphone, nalbuphine, oxymorphone and pentazocine in equine urine.

We have investigated the action of five sources of beta-glucuronidase enzymes on the hydrolysis of glucuronides of apomorphine, butorphanol, hydromorphone, nalbuphine, oxymorphone and pentazocine in equine urine. For all glucuronides tested, Patella vulgata beta-glucuronidase yielded the largest thin layer chromatographic (TLC) spots. For oxymorphone, P. vulgata was the only treatment to yield detectable TLC spots under test parameters. For these six drugs, TLC spot size and chromatographic quality were compared between control horses and horses pretreated with furosemide four hours earlier. Furosemide pretreatment produced a statistically significant increase in spot size and was found to enhance chromatogram quality. These findings support previous suggestions that P. vulgata is a superior drug-glucuronide hydrolyzing enzyme. They also support earlier reports that administration of furosemide at four hours pre-race is unlikely to result in significant interference with routine drug testing procedures.

Animals↗
PubMed1982

Morphine glucuronide hydrolysis: superiority of beta-glucuronidase from Patella vulgata.

beta-Glucuronidase from Patella vulgata, Helix aspersa, Helix pomatia, and bovine liver were evaluated for usefulness in routine hydrolysis of drug-glucuronic acid conjugates from equine urine samples. Factors affecting the reaction rate (enzyme concentration, ligand concentration, temperature, and pH) were optimized. A 3-h incubation at 65 degrees C with 5000 U of beta-glucuronidase from P. vulgata per milliliter of urine resulted in complete hydrolysis of all morphine glucuronide in the urine samples. Not only was the enzyme preparation from P. vulgata the most cost-effective beta-glucuronidase source studied, but also its thermal stability is such that it can be used at a temperature high enough to substantially shorten the incubation interval. Preliminary work on other drugs that form glucuronide conjugates indicates that this same procedure is similarly superior for use in their hydrolysis.

Animals↗
PubMed1981

Gas/liquid chromatographic analysis of pemoline in biological fluids using electron capture detection.

An analytical gas/liquid chromatographic (GLC) protocol is described for the quantitation of pemoline in biological fluids of the horse. Plasma samples containing known quantities of pemoline and its analog as an internal standard (IS) were deproteinized with 5-sulfosalicylic acid, heated at 80 degree C, and centrifuged. 5-Phenyl-2,4-oxazolidinedione, the hydrolytic product of pemoline in acid medium, was extracted with dichloromethane (DCM). The organic layer was in turn re-extracted with 1% NaHCO3. The aqueous layer was acidified with HCI, and re-extracted with DCM, which was evaporated to dryness. The resulting residue was methylated with ethereal diazomethane. The methylated dione was dissolved in benzene, and analyzed with a gas/liquid chromatograph equipped with a tritiated scandium foil (Sc3H) electron capture detector (ECD). Urine samples to which pemoline was added were hydrolyzed with hydrochloric acid and carried through the analytical procedure in a manner similar to the plasma, except that the urine was further washed with lead acetate solution prior to the sodium bicarbonate extraction. The lower limits of detection were found to be 0.05 microgram/ml for plasma and 0.1 microgram/ml for urine when 1.0 ml of sample was used. This procedure can be used for pemoline detection control in international sporting events.

Animals↗
PubMed1981

Pharmacology of narcotic analgesics in the horse: quantitative detection of morphine in equine blood and urine and logit-Log transformations of this data.

Morphine was detected in equine biological fluids by a combination of liquid-liquid extraction and column chromatography, followed by derivatization and gas-liquid chromatographic assay, using electron capture detector. Recovery of morphine from the equine biological samples was poor. However, despite an overall recovery of less than 20%, this method had a detection limit of 0.2 ng/ml. Addition of 5,000 U of bovine liver beta-glucuronidase/ml of urine enabled detection of the drug in urine for up to 144 hours after horses were given 0.1 mg of morphine/kg of body weight. Morphine was found for at least 24 hours in serum samples. An adaptation of logit-log transformation of gas-liquid chromatographic data for linearization over 3 log units suggested a simple adaptation to existing semiautomated data handling systems.

Animals↗
PubMed1977

Drug interactions in the horse: effects of chloramphenicol, quinidine, and oxyphenbutazone on phenylbutazone metabolism.

The plasma half-life of phenylbutazone in horses was not increased after pretreatment with chloramphenicol or quinidine, but was increased after oxyphenbutazone. This increased plasma half-life after oxyphenbutazone is consistent with observations in other species and suggests that oxyphenbutazone inhibits the metabolism of phenylbutazone in horses. Lack of inhibition of phenylbutazone metabolism in the horse by chloramphenicol and quinidine is inconsistent with results obtained in other species.

Animals↗
PubMed1976

Mefanamic acid blood and urine levels in the horse determined by derivative gas-liquid chromatography-electron capture.

Mefenamic acid is extracted from biological fluids and is acylated with pentafluoropropionic anhydride to form a derivative possessing high electron affinity. The derivative is analyzed by gas-liquid chromatography with an electron capture detector. The method is particularly valuable for determining drug levels in blood where small sample and/or drug concentrations are available.

Animals↗